Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic urothelial carcinoma in adults. This guidance only includes recommendations for untreated urothelial carcinoma when cisplatin-based chemotherapy is unsuitable. NICE are developing separate guidance for urothelial carcinoma that has progressed after platinum-containing chemotherapy.
This report addresses the extremely important area of epilepsy in the field of intellectual disability (ID), also known as learning disability. Epilepsy and ID are two conditions that carry stigma and can lead to social isolation. An individual who experiences
This guideline covers identifying and managing depression in children and young people aged between 5 and 18 years. Based on the stepped care model, it aims to improve recognition and assessment and promote effective treatments for mild, moderate and severe
This guideline sets out how health and social care staff can support people to be independent following a hospital stay or when daily life at home becomes too difficult. It covers how to assess intermediate care needs, including setting goals with the person
This guidance is aimed at DH group bodies (including CCGs, NHS trusts, NHS foundation trusts and arm’s length bodies) to help them complete their statutory annual reports and accounts for 2017 to 2018.
Evidence-based recommendations on SecurAcath for securing percutaneous catheters. NICE has published a medtech innovation briefing on SecurAcath for an emerging indication (securing cerebrospinal fluid catheters) for which the evidence and use are still developing.
A resource to help commissioners and providers of NHS-commissioned services create, review and sustain, safe and effective specialist mental health services. This is a final draft for comment before the publication of a final, revised version later this year. It aims to
Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.
March 2017: under the original patient access scheme the company provided 2×45‑mg pre-filled syringes, for patients who needed the higher dose of 90‑mg, at the same total cost to the NHS as for a single 45‑mg pre-filled syringe. The patient
March 2017 Amendement: under the original patient access scheme the company provided 2×45‑mg pre-filled syringes, for patients who needed the higher dose of 90‑mg, at the same total cost to the NHS as for a single 45‑mg pre-filled syringe. The
Updates to QS13 March 2017: Statement 11 on care in the last days of life has been removed. This is because NICE has published a quality standard for care of dying adults in the last days of life, which covers
The RCN recognises that trans people frequently experience prejudice and discrimination. The nursing community can, through its professional actions and interests, work to eliminate this at both an individual and a societal level in partnership with a range of organisations,
This guide is aimed at primary care and commissioners, particularly GPs, who provide care plan reviews. It is designed to help improve care planning in dementia by supporting a standardised approach, highlighting good practice, ensuring alignment with relevant crosscondition care
Updated NICE Guidline. March 2017: Recommendation 18.104.22.168 and its footnote have been updated as the source guidance they were taken from has been replaced. The footnote to recommendation 22.214.171.124 has been amended to give the definition of aspirin intolerance rather
The content of this evidence summary was updated in March 2017. See summaries of product characteristics (SPC), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information.
Report that outlines actions to be taken by the general public, emergency services, and hospital services to improve the survival rate of people suffering cardiac arrest. These include improving public awareness of how to perform CPR, establishing an effective pathway of
This document clarifies existing guidance on primary care inspection and outlines how CQC will inspect and regulate providers of digital primary care services.
This quality standard covers increasing vaccine uptake among children and young people aged under 19 in groups and settings that have low immunisation coverage. It describes high-quality care in priority areas for improvement.
This quality standard covers the clinical care of adults (aged 18 and over) who are dying, during the last 2 to 3 days of life. It describes high-quality care in priority areas for improvement. It does not cover care before
This revised guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and